


LCH-12 Protocol



Abbreviation: AD-p, active disease progression; GR, good response; MFB, multifocal bone; MS, multi system; NR, no response; PD, progression disease; PR, partial response.

Treatment element	Daily dose	Days of application
Induction A: weeks 1–6 for MFB and MS disease		
Cytarabine (IV over 6 hours)	100 mg/m ²	1–5, 15–19, 29–33
Vincristine (IV push)	1.5 mg/m ² (maximum 2.0 mg) ^{a)}	1, 15, 29
Prednisolone (PO/IV)	40 mg/m ² (maximum 60 mg)	1–28
Prednisolone (PO/IV)	20 mg/m ²	29–35
Prednisolone (PO/IV)	10 mg/m ²	36–42
Early Maintenance A: weeks 7–30 for responders to Induction A		
Cytarabine (IV over 2 hours)	150 mg/m ²	1, 29, 57, 85, 113, 141
Methotrexate (IV push)	20 mg/m ²	15, 43, 71, 99, 127, 155
Vincristine (IV push)	1.5 mg/m ² (maximum 2.0 mg) ^{a)}	1, 15, 29, 43, 57, 71, 85, 99, 113, 127, 141, 155
Prednisolone (PO/IV)	40 mg/m ² (maximum 60 mg)	1–4, 15–17, 29–32, 43–45, 57–60, 71–73, 85–88, 99–101, 113–116, 127–129, 141–144, 155–157
Late Maintenance C: weeks 31–54 or 37–60 for MS disease following Early Maintenance A or B		
6-mercaptopurine (PO)	30 mg/m ²	1–168
Vinblastine (IV push)	6 mg/m ² (maximum 6 mg) ^{b)}	1, 29, 57, 85, 113, 141
Prednisolone (PO/IV)	40 mg/m ² (maximum 60 mg)	1–5, 29–33, 57–61, 85–89, 113–117, 141–145
Methotrexate (PO)	20 mg/m ²	15, 43, 71, 99, 127, 155
Induction B: weeks 7–12 for patients with MS disease and NR to Induction A		
Adriamycin (IV push)	35 mg/m ²	1, 15, 29
Cyclophosphamide (IV push)	200 mg/m ²	1–5, 15–19, 29–33
Vincristine (IV push)	1.5 mg/m ² (maximum 2.0 mg) ^{a)}	1, 15, 29
Prednisolone (PO/IV)	40 mg/m ² (maximum 60 mg)	1–5, 15–19, 29–33
Early Maintenance B: weeks 13–36		
Adriamycin (IV push)	35 mg/m ²	1, 57, 113
Methotrexate (IV over 1 hour)	60 mg/m ²	15, 43, 71, 99, 127, 155
Cyclophosphamide (IV push)	200 mg/m ²	29, 85, 141
Vincristine (IV push)	1.5 mg/m ² (maximum 2.0 mg) ^{a)}	1, 29, 57, 85, 113, 141
Prednisolone (PO/IV)	40 mg/m ² (maximum 60 mg)	1–5, 15–17, 29–33, 43–45, 57–61, 71–73, 85–89, 99–101, 113–117, 127–129, 141–145, 155–157

PO, orally; IV, intravenous infusion.

a) Doses of vincristine were 0.05 mg/kg in patients weighing less than 10 kg.

b) Doses of vinblastine were 0.2 mg/kg in patients weighing less than 10 kg.